Experience With a New Butyrqphenone Derivative (Burqnil)

Vangtorp, A; Simmelsgaard, H; Mellergaard, Mogens

doi:10.1111/j.1600-0447.1968.tb01996.x

Cited by 6 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Melperone has already been well documented in the treatment of unrest, agony and confusion in the elderly [Ljungberg and Bjerkenstedt, 1972;Harnryd et al, 1974;Beck-Nielsen and Clausen, 1970;Engstrand, 1967;Norgárd et al, 1967;Simrnelsgaard et al, 1967;Vangtorp et al, 1968;Viskum, 1970;Rohde. 1975;Birkmayer and Danielczyk, 1969;Kirkegaard et al.…”

Section: Introductionmentioning

confidence: 99%

Melperone in Low Doses in Anxious Neurotic Patients

Pöldinger¹

1984

Neuropsychobiology

View full text Add to dashboard Cite

60 anxious neurotic outpatients completed a double-blind comparative 2 week clinical study of the anxiolytic effect of melperone 10 mg t.i.d. and 25 mg t.i.d. versus placebo. The efficacy was assessed by the Hamilton Anxiety Scale and Clinical Global Impressions. At the end of the 1 st and the 2nd week of treatment, the reduction in the Hamilton scores was significantly greater in the melperone groups than in the placebo group, but there was no significant difference in the improvement of the two melperone groups. Similar findings were true for the global assessment. The adverse effects recorded were generally mild and transient, tiredness being the most frequent in both the placebo and melperone groups. No laboratory abnormalities were attributable to melperone. A nonsignificant reduction in systolic blood pressure was observed in the melperone groups, probably due to the antianxiety effect. It is concluded that melperone, in low doses, appears to be both safe and effective as an antianxiety agent. The results indicate that melperone could be a realistic alternative to the benzodiazepines.

show abstract

Section: Introductionmentioning

confidence: 99%

Melperone in Low Doses in Anxious Neurotic Patients

Pöldinger¹

1984

Neuropsychobiology

View full text Add to dashboard Cite

show abstract

Haloperidol versus chlorpromazine for schizophrenia

Leucht

Kitzmantel

Kane

et al. 2008

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Given that haloperidol and chlorpromazine are global standard antipsychotic treatments for schizophrenia, it is surprising that less than 800 people have been randomised to a comparison and that incomplete reporting still makes it difficult for anyone to draw clear conclusions on the comparative effects of these drugs. However, it seems that haloperidol causes more movement disorders than chlorpromazine, while chlorpromazine is significantly more likely to lead to hypotonia. We are surprised to have to say that we feel further, large, well designed, conducted and reported studies are required.

show abstract